These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1465 related items for PubMed ID: 23872058
1. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. Methods; 2014 Jan 01; 65(1):114-26. PubMed ID: 23872058 [Abstract] [Full Text] [Related]
2. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K. Mol Immunol; 2014 Mar 01; 58(1):132-8. PubMed ID: 24334029 [Abstract] [Full Text] [Related]
3. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding. Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P. MAbs; 2015 Mar 01; 7(4):743-51. PubMed ID: 25970007 [Abstract] [Full Text] [Related]
4. IgG2m4, an engineered antibody isotype with reduced Fc function. An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, Gibson CR, Harvey BR, Montgomery D, Zaller D, Wang F, Strohl W. MAbs; 2009 Mar 01; 1(6):572-9. PubMed ID: 20073128 [Abstract] [Full Text] [Related]
5. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M. Glycobiology; 2007 Jan 01; 17(1):104-18. PubMed ID: 17012310 [Abstract] [Full Text] [Related]
6. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface. Teplyakov A, Zhao Y, Malia TJ, Obmolova G, Gilliland GL. Mol Immunol; 2013 Nov 01; 56(1-2):131-9. PubMed ID: 23628091 [Abstract] [Full Text] [Related]
7. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. Grevys A, Bern M, Foss S, Bratlie DB, Moen A, Gunnarsen KS, Aase A, Michaelsen TE, Sandlie I, Andersen JT. J Immunol; 2015 Jun 01; 194(11):5497-508. PubMed ID: 25904551 [Abstract] [Full Text] [Related]
8. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ. MAbs; 2015 Jun 01; 7(3):494-504. PubMed ID: 25933349 [Abstract] [Full Text] [Related]
10. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design. Caaveiro JM, Kiyoshi M, Tsumoto K. Immunol Rev; 2015 Nov 01; 268(1):201-21. PubMed ID: 26497522 [Abstract] [Full Text] [Related]
16. Engineering IgG1 Fc Domains That Activate the Complement System. Lee CH, Delidakis G. Methods Mol Biol; 2022 Nov 01; 2421():187-200. PubMed ID: 34870820 [Abstract] [Full Text] [Related]